Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the sale, the vice president now directly owns 33,492 shares in the company, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO opened at $54.00 on Thursday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market cap of $3.77 billion, a PE ratio of -14.40 and a beta of -0.19. The company’s fifty day moving average is $29.31 and its 200 day moving average is $28.51. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AKRO shares. Morgan Stanley lifted their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday. Citigroup upped their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright lifted their target price on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday. Finally, Canaccord Genuity Group increased their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Akero Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $61.57.

Institutional Trading of Akero Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. abrdn plc raised its holdings in Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company’s stock valued at $7,505,000 after buying an additional 146,424 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Akero Therapeutics by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock valued at $412,000 after acquiring an additional 1,446 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after purchasing an additional 583,486 shares during the period. Exome Asset Management LLC bought a new stake in shares of Akero Therapeutics in the third quarter worth about $2,212,000. Finally, Barclays PLC increased its holdings in Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after purchasing an additional 71,652 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.